

CDC's 2022 CLINICAL PRACTICE GUIDELINE FOR PRESCRIBING OPIOIDS FOR PAIN WB4701

PROGRAM DESCRIPTION: This enduring activity provides an overview of the Centers for Disease Control and Prevention's 2022 Clinical Practice Guideline for Prescribing Opioids for Pain. This module describes the 2022 Clinical Practice Guideline recommendations intended for clinicians providing pain care, including those prescribing opioids for outpatients with acute, subacute, and chronic pain and how to apply the recommendations as flexible standards of care to enable patient-centered decision-making.

OBJECTIVES:

At the conclusion of the session, the participant should be able to:

1. Explain the purpose of the 2022 Clinical Practice Guideline
2. Describe the recommendations in the 2022 Clinical Practice Guideline
3. Describe the guiding principles that broadly inform implementation across the recommendations in the 2022 Clinical Practice Guideline
4. Identify interprofessional care coordination strategies that support implementation of the 2022 Clinical Practice Guideline

FACULTY/ CREDENTIALS:

Christina A. Mikosz, MD, MPH, Lead Medical Officer, Division of Overdose Prevention, National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention

Molly Dowling, MPH, Health Communications Specialist, Division of Overdose Prevention, National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention

ORIGINATION DATE: 04/28/2023

EXPIRATION DATE: 04/28/2025

URL: <https://www.cdc.gov/opioids/healthcare-professionals/training/Overview.html>

HARDWARE/SOFTWARE: Computer Hardware; Internet Connection;

MATERIALS:	Browser None
TARGET AUDIENCE:	Physicians, Registered Nurses
PREREQUISITES:	None
FORMAT:	This activity is Web-based .
CONTACT INFORMATION:	Division of Overdose Prevention, National Center for Injury Prevention and Control 800-232-4636

ACCREDITATION STATEMENTS:



In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **1** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **1** nursing contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer **0.1** CEU's for this program

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WB4701 CDC's 2022 Clinical Practice Guideline for Prescribing Opioids for Pain** please visit [TCEO](#) and follow these [9 Simple Steps](#) before **04/28/2025**.

Complete the activity

Complete the Evaluation at www.cdc.gov/GetCE

Pass the posttest at **80%** at www.cdc.gov/GetCE

FEES: No fees are charged for CDC's CE activities.